Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Protocols / Standard Specimen Reference Set: Colon

Standard Specimen Reference Set: Colon

251
Brenner, DeanUniversity of Michigan
Case/control
UNKNOWN
G.I. and Other Associated Cancers Research Group

The Early Detection Research Network, Great Lakes-New England Clinical, Epidemiological and Validation Center (GLNE CVC) announces the availability of serum, plasma and urine samples for the early detection for colon cancer and validation studies.

Two prospective studies were used to collect samples to make this reference set. GLNE 001, (Preliminary Clinical Characterization of Serum, Plasma, and Urine Biomarkers for Colorectal Neoplasms) was a prospective, cross-sectional clinical trial to collect serum, plasma, urine, and common data elements on subjects undergoing routine screening colonoscopy or subjects undergoing surgery or endoscopy for colon cancer. GLNE 007 (Evaluation of Stool Based Markers for the Early Detection of Colorectal Cancers and Adenomas) is an on-going prospective, cross-sectional clinical to collect serum, plasma, urine, stool, and common data elements. In both protocols, subjects were undergoing routine colonoscopy (or being seen in surgery clinic for colorectal cancer) when the samples were collected. Samples were collected while the target lesions were still in place in the colon. Subjects were either normal (without adenomas or cancer), with pathologically confirmed adenomas or pathologically confirmed colorectal adenocarcinoma. Exclusion criteria for both protocols included known hepatitis C or HIV, ulcerative colitis, Crohns’s Disease or IBD, history of cancer within 3 years, or genetic colon diseases including FAP or HNPCC. Samples were collected from 4 sites around North America.

There are currently no biomarkers annotated for this protocol.

No datasets are currently associated with this protocol.


Announcement 11/20/2014

New Round of EDRN FOAs

The RFAs for EDRN have been released:
- Biomarker Developmental Laboratories (U01),
- Clinical Validation Centers (U01),
- Biomarker Reference Laboratories (U24),
- Data Management and Coordinating Center (U24).

EDRN Renewal flyer NOTE-New receipt deadline for applications submitted for all EDRN FOAs is January 20, 2015, by 5:00 PM local time of applicant organization.

There will be a Pre-Application webinar to discuss each of the four individual EDRN FOAs on Tuesday, December 2nd, 2014, from 1pm-5pm (Eastern). Potential applicants interested in participating in the webinar should send a message to Dr. Sharmistha Ghosh (ghoshjanjigias@mail.nih.gov) no later than 5:00 p.m. (EST) November 21, 2014. Please mention the FOA of interest in the subject line.

Announcement 10/07/2014

EDRN Patient Advocates will host an EDRN Advocacy Educational Webinar, Biomarkers for Prostate Cancer Detection and Monitoring, on Monday, January 12th, 2015, at 1 p.m. EDT / 10 a.m. PDT. Registration is not required for this. Please click for more information.